Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Mixed gangliocytoma-pituitary adenoma in the sellar region: a large-scale single-center experience
First author：Yang Bao, Bao
Corresponding author：Wang Shuo, Shuo
essential_information
- Person in charge：Yang Bao, Bao
- Data Sources： OTHERS
- Number of papers：OTHERS20190724
- Published time：2018-10-01
2018-10-01
Published articles
Journal：Acta Neurochir (Wien)
Publication type: Original Article
IF(IF): 1.834
PMID: 30109498 Link To Pubmed Full text Download
Background And Purpose
Method
We retrospectively reviewed the clinical, radiological, and histopathological profiles from a series of 20 patients with sellar mixed gangliocytoma-pituitary adenomas. All patients underwent surgical tumorectomy via an endoscopic or microscopic transsphenoidal approach. Perioperative magnetic resonance imaging (MRI) and computed tomography (CT) data were reviewed. Immunohistochemical stains and electron microscopy examination were performed. Follow-up outcomes were presented.
Conclusion
The clinical and neuroimaging features of sellar mixed gangliocytoma-pituitary adenomas are non-specific, and invasion into the cavernous sinus is common. Surgical resection via a transsphenoidal approach is the preferred treatment, and the surgical outcomes are favorable. Moreover, our histopathological findings are more likely to support the theory that mixed gangliocytoma-pituitary adenoma originates from the neuronal transdifferentiation of adenomatous cells.
Main results
This case series consisted of 13 females and seven males (age range, 20-59 years; mean age, 42.3 ± 11.2 years). Preoperative endocrine examination showed elevated growth hormone (GH) in nine patients and hyperprolactinemia in eight patients. The tumors were positive for GH in 15 cases, prolactin in 13 cases, adrenocorticotropic hormone in three cases, and thyroid-stimulating hormone in one case. Gross total resection was achieved in 15 patients, and subtotal resection in five patients. During an average follow-up period of 42.5 ± 29.0 months, no recurrence was noted.